Scarica l'app Stockscreener
28.88
2.23%
0.63
Dopo l'orario di chiusura:
28.52
-0.36
-1.25%
Precedente Chiudi:
$28.25
Aprire:
$28.86
Volume 24 ore:
305.57K
Relative Volume:
0.85
Capitalizzazione di mercato:
$1.38B
Reddito:
-
Utile/perdita netta:
$-111.48M
Rapporto P/E:
-10.08
EPS:
-2.865
Flusso di cassa netto:
$-88.09M
1 W Prestazione:
+9.06%
1M Prestazione:
-4.37%
6M Prestazione:
+15.66%
1 anno Prestazione:
+187.36%
Intervallo 1D:
$28.57
$30.72
Intervallo di 1 settimana:
$26.01
$30.72
Portata 52W:
$7.73
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Nome
Rapport Therapeutics Inc
Settore
Industria
Telefono
857-321-8020
Indirizzo
99 HIGH STREET, BOSTON
Compare RAPP vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
28.88 | 1.35B | 0 | -111.48M | -88.09M | -2.865 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-02 | Iniziato | Wells Fargo | Overweight |
| 2025-11-19 | Iniziato | BTIG Research | Buy |
| 2025-09-16 | Iniziato | Truist | Buy |
| 2025-08-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-04-08 | Iniziato | Citizens JMP | Mkt Outperform |
| 2024-07-02 | Iniziato | Jefferies | Buy |
| 2024-07-02 | Iniziato | Stifel | Buy |
| 2024-07-02 | Iniziato | TD Cowen | Buy |
Mostra tutto
Rapport Therapeutics Inc Borsa (RAPP) Ultime notizie
Geopolitics Watch: Will Rapport Therapeutics Inc stock go up in YEAR2026 Price Targets & AI Driven Price Predictions - baoquankhu1.vn
(RAPP) Risk Channels and Responsive Allocation - Stock Traders Daily
RAPP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
How Investors May Respond To Rapport Therapeutics (RAPP) Licensing RAP-219 To Tenacia In Greater China - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Immutep Ltd (OtherPRRUF), Coya Therapeutics, Inc. (COYA) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Aug Selloffs: Why is Rapport Therapeutics Inc stock going up2026 Trends & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Buyout Rumor: Does Rapport Therapeutics Inc have strong fundamentals2026 Highlights & Long-Term Capital Growth Strategies - baoquankhu1.vn
Sell Signal: Will Rapport Therapeutics Inc benefit from AI trends2026 Drop Watch & Fast Gain Swing Trade Alerts - baoquankhu1.vn
What hedge funds are buying Rapport Therapeutics Inc2026 Fundamental Recap & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Update Recap: Why is Rapport Therapeutics Inc stock going up2026 Volume Leaders & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Whats the outlook for Rapport Therapeutics Incs sectorWeekly Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
Take Profit: Is Rapport Therapeutics Inc undervalued by DCF analysisWeekly Loss Report & Stock Portfolio Risk Management - baoquankhu1.vn
Truist reiterates Rapport Therapeutics stock rating on phase 3 plans By Investing.com - Investing.com Canada
Truist reiterates Rapport Therapeutics stock rating on phase 3 plans - Investing.com
Baker BROS. Advisors LP Has $45.95 Million Position in Rapport Therapeutics, Inc. $RAPP - MarketBeat
HC Wainwright & Co. Initiates Coverage of Rapport Therapeutics (RAPP) with Buy Recommendation - MSN
Rapport Therapeutics (NASDAQ:RAPP) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Why Rapport Therapeutics (RAPP) Is Down 7.9% After RAP-219 China Deal And Shelf Filing - simplywall.st
Q1 EPS Forecast for Rapport Therapeutics Boosted by Analyst - Defense World
Q1 EPS Estimate for Rapport Therapeutics Lifted by Analyst - MarketBeat
Analysts Offer Insights on Healthcare Companies: Rapport Therapeutics, Inc. (RAPP), SAB Biotherapeutics (SABS) and Encompass Health (EHC) - The Globe and Mail
(RAPP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives $50.80 Consensus PT from Brokerages - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 7.7%Should You Sell? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Sana Biotechnology (SANA) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Equities Analysts Offer Predictions for RAPP FY2030 Earnings - MarketBeat
Capital International Investors Buys 800,000 Shares of Rapport Therapeutics, Inc. $RAPP - MarketBeat
Day Trade: Will Rapport Therapeutics Inc stock go up in YEARMarket Weekly Review & Scalable Portfolio Growth Methods - baoquankhu1.vn
Rapport Therapeutics (NASDAQ:RAPP) Price Target Raised to $46.00 at Wells Fargo & Company - MarketBeat
BTIG raises Rapport Therapeutics stock price target on trial progress By Investing.com - Investing.com Canada
Jones Trading reiterates Rapport Therapeutics stock rating on epilepsy progress - Investing.com Canada
Stifel reiterates Rapport Therapeutics stock rating after results By Investing.com - Investing.com Canada
Rapport Therapeutics Inc (RAPP) Reports a Wider Loss for Q4 2025 - AlphaStreet
Advancing RAP-219: Phase 3 Progress, 2026 Catalysts, and Strategic China Partnership Support a Buy Rating - TipRanks
Rapport Therapeutics Reports Strong 2025 Results, Advances RAP-219 Epilepsy Drug to Phase 3 with $490M Cash Runway - Minichart
Rapport’s RAP-219 gets more phase III funding with Tenacia deal - BioWorld MedTech
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Down on Disappointing Earnings - MarketBeat
Rapport Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Rapport Therapeutics: Advancing Precision Neuroscience with RAP Technology Platform for Neurological and Psychiatric Disorders 4048 - Minichart
Rapport Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Flash (RAPP) Rapport Therapeutics Posts Q4 Net Loss $0.72 a Share, vs. FactSet Est of $0.70 Loss - marketscreener.com
Rapport Therapeutics (NASDAQ:RAPP) Posts Quarterly Earnings Results, Misses Estimates By $0.07 EPS - MarketBeat
Rapport Therapeutics 2025 10‑K: Net loss $111.5M, EPS $(2.86) - TradingView
Rapport Therapeutics (Nasdaq: RAPP) details 2025 losses and RAP‑219 epilepsy progress - Stock Titan
RAP-219 epilepsy drug cut seizures 77.8% in Phase 2a trial - Stock Titan
Citizens reiterates Rapport Therapeutics stock rating on seizure drug potential By Investing.com - Investing.com Canada
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Maintained Buy: RAPP analyst rating on Rapport Therapeutics, Inc. Common Stock Mar 2026 - Meyka
Top Executive’s Surprise Stock Move Shakes Up Rapport Therapeutics - TipRanks
Cheryl Gault Sells 2,014 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat
BTIG reiterates Rapport Therapeutics stock rating citing selectivity By Investing.com - Investing.com Canada
Rapport Therapeutics Inc Azioni (RAPP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):